Company Introduction
Vetnostrum Animal Health Co., Ltd. (Vetnostrum) is a member of YungShin Global Holding Corporation (Stock Code: 3705). In 2016, Yung Shin Pharmaceutical Industrial Co. acquired a foreign pharmaceutical company and integrated its existing Animal Health Division, establishing one of Taiwan’s leading large-scale veterinary pharmaceutical manufacturers.
Vetnostrum is mainly engaged in the production and sales of animal health products, including veterinary pharmaceuticals and feed additives. The company holds over 300 domestic and international veterinary product licenses, with its offerings categorized into four major types: therapeutic drugs, medicated feed additives, non-medicated feed additives, and pet-use drugs and supplements. Its primary clients include major domestic and international feed mills, livestock farms, distributors, and veterinary hospitals and clinics. Partners include Novus (a private animal health company under Mitsui & Co., Japan), Great Wall Enterprise, Charoen Pokphand Enterprise, and the Livestock Division of Taiwan Sugar Corporation. Vetnostrum has also established its own brand, Koolpal, with both online and offline sales channels, such as MOMO, Etipets, Wonder Pets, and We Can Medicines.
Taiwan’s Largest and First WHO GMP-Certified Veterinary Drug Manufacturer
Leveraging the pharmaceutical expertise of Yung Shin Pharmaceutical Industrial Co., Vetnostrum applies human-grade pharmaceutical standards across R&D, production, distribution, and technical services, providing a comprehensive solution for animal health.
Vetnostrum is the first veterinary drug manufacturer in Taiwan to obtain WHO GMP certification. It also holds GMP, FAMI-QS, and ISO 9001 certifications. With 15 production lines and over 350 products, it has the most complete veterinary product range in Taiwan. The company is equipped with sterile injectable production lines—both general and high-potent types—that meet human pharmaceutical standards, enabling the supply of high-quality veterinary injectable products. By combining its diverse product offerings with technical services from veterinarians and consultant teams, Vetnostrum fully meets the needs of veterinarians and farmers.
Strong R&D Capabilities and In-House Product Development
Vetnostrum has a complete R&D team responsible for product development and formulation, analytical method establishment, and product registration in Taiwan and around the world. To continuously innovate and operate sustainably, Vetnostrum has set up an R&D laboratory to adopt new technologies and develop new animal health products.
The company also offers customized formulations and specifications based on client needs and carries out various regulatory requirements and tests. Vetnostrum integrates resources from industry, government, and academia—including the Ministry of Agriculture, Agricultural Technology Research Institute, and leading universities with veterinary medicine, animal science, aquaculture, and aquatic biology departments. Alongside its internal R&D team, Vetnostrum advances technology transfers, pilot studies, and efficacy trials to continuously enhance its research and innovation capacity.
Stable Profitability and Sustainability
In terms of financial performance, Vetnostrum reported operating revenue of NT$1,185 million in 2022, which grew to NT$1,294 million in 2024. Operating profit increased from NT$125 million to NT$171 million, and the operating margin rose from 10.51% to 13.19%, showing a significant improvement in profitability.
Pre-tax net income increased from NT$131 million in 2022 to NT$170 million in 2024. Earnings per share also increased from NT$1.69 to NT$2.06, indicating steady growth in profit and financial stability.
Outlook and Vision
Vetnostrum will continue to strengthen its core capabilities, improve product competitiveness and brand influence, and move toward becoming the leading animal health brand in the Asia-Pacific region. The company will keep building momentum, consolidating Taiwan’s domestic demand, and actively expanding its presence across Asia.
Vetnostrum is laying a solid foundation for its business strategy .The company will significantly expand its production capacity and strengthen its innovation efforts in the global animal health market—reaffirm its commitment and mission: Rooted in Taiwan, advancing worldwide.